# A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

> **NCT01986855** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 468 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Ertugliflozin 5 mg
- **DRUG:** Placebo 5 mg
- **DRUG:** Ertugliflozin 10 mg
- **DRUG:** Placebo 10 mg

## Key facts

- **NCT ID:** NCT01986855
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-02
- **Primary completion:** 2016-09-28
- **Final completion:** 2016-09-28
- **Target enrollment:** 468 (ACTUAL)
- **Last updated:** 2018-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01986855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01986855, "A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01986855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*